Document is current
Any future updates will be listed below
-
Authors
El-Masri, Bilal M. https://orcid.org/0000-0003-4963-4859
Andreasen, Christina M. https://orcid.org/0000-0002-2624-5677
Laursen, Kaja S.
Kofod, Viktoria B.
Dahl, Xenia G. https://orcid.org/0000-0002-4922-2478
Nielsen, Malene H.
Thomsen, Jesper S. https://orcid.org/0000-0001-9386-6679
Brüel, Annemarie https://orcid.org/0000-0003-4833-0888
Sørensen, Mads S.
Hansen, Lars J.
Kim, Albert S. https://orcid.org/0000-0001-5832-0224
Taylor, Victoria E.
Massarotti, Caitlyn
McDonald, Michelle M. https://orcid.org/0000-0002-3928-2506
You, Xiaomeng https://orcid.org/0000-0003-2132-1404
Charles, Julia F. https://orcid.org/0000-0002-5875-314X
Delaisse, Jean-Marie https://orcid.org/0000-0001-7370-1500
Andersen, Thomas L. https://orcid.org/0000-0002-6981-7276
-
Funding
Funding for this research was provided by:
Velux Fonden (VELUX25723)
Odense University Hospital’s Fund for Free Research (A5111), the Region of Southern Denmark’s Fund for Free Research
- License Information
-
More Information
Article History
Received: 10 January 2024
Revised: 26 July 2024
Accepted: 1 August 2024
First Online: 18 October 2024
Competing interests
: M.M.M. and X.G.D. have received honoraria from Amgen. J.F.C. has participated in Alexion, Kyowa Kirin and Amgen advisory boards. J.F.C. has received funding from Novartis. M.B. and J.S.T. have received a research grant from Keros Therapeutics for an unrelated study. T.L.A. has collaborated with Amgen and is the custodian of the biopsies from the FREEDOM study, and in part received free reagents from ACD bioscience (now part of the Bio-Techne Corporation) for the specific study. Amgen Inc provided the OPG:Fc under a material transfer agreement.
